Keryx ferric citrate OK'd, but label alarms investors
This article was originally published in Scrip
Executive Summary
Keryx Biopharmaceuticals won approval from the FDA on 5 September as expected of its phosphate binder ferric citrate to control serum phosphorus levels in patients with chronic kidney disease on dialysis, but without the initial brand name selected for the drug and with a warning about iron overload, which had investors alarmed.